Coccidioidomycosis and Histoplasmosis in Equines: an Overview to Support the Accurate Diagnosis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Estimated Burden of Serious Fungal Infections in Ghana
Journal of Fungi Article Estimated Burden of Serious Fungal Infections in Ghana Bright K. Ocansey 1, George A. Pesewu 2,*, Francis S. Codjoe 2, Samuel Osei-Djarbeng 3, Patrick K. Feglo 4 and David W. Denning 5 1 Laboratory Unit, New Hope Specialist Hospital, Aflao 00233, Ghana; [email protected] 2 Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, P.O. Box KB-143, Korle-Bu, Accra 00233, Ghana; [email protected] 3 Department of Pharmaceutical Sciences, Faculty of Health Sciences, Kumasi Technical University, P.O. Box 854, Kumasi 00233, Ghana; [email protected] 4 Department of Clinical Microbiology, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi 00233, Ghana; [email protected] 5 National Aspergillosis Centre, Wythenshawe Hospital and the University of Manchester, Manchester M23 9LT, UK; [email protected] * Correspondence: [email protected] or [email protected] or [email protected]; Tel.: +233-277-301-300; Fax: +233-240-190-737 Received: 5 March 2019; Accepted: 14 April 2019; Published: 11 May 2019 Abstract: Fungal infections are increasingly becoming common and yet often neglected in developing countries. Information on the burden of these infections is important for improved patient outcomes. The burden of serious fungal infections in Ghana is unknown. We aimed to estimate this burden. Using local, regional, or global data and estimates of population and at-risk groups, deterministic modelling was employed to estimate national incidence or prevalence. Our study revealed that about 4% of Ghanaians suffer from serious fungal infections yearly, with over 35,000 affected by life-threatening invasive fungal infections. -
Coccidioides Immitis
24/08/2017 FUNGAL AGENTS CAUSING INFECTION OF THE LUNG Microbiology Lectures of the Respiratory Diseases Prepared by: Rizalinda Sjahril Microbiology Department Faculty of Medicine Hasanuddin University 2016 OVERVIEW OF CLINICAL MYCOLOGY . Among 150.000 fungi species only 100-150 are human pathogens 25 spp most common pathogens . Majority are saprophyticLiving on dead or decayed organic matter . Transmission Person to person (rare) SPORE INHALATION OR ENTERS THE TISSUE FROM TRAUMA Animal to person (rare) – usually in dermatophytosis 1 24/08/2017 OVERVIEW OF CLINICAL MYCOLOGY . Human is usually resistant to infection, unless: Immunoscompromised (HIV, DM) Serious underlying disease Corticosteroid/antimetabolite treatment . Predisposing factors: Long term intravenous cannulation Complex surgical procedures Prolonged/excessive antibacterial therapy OVERVIEW OF CLINICAL MYCOLOGY . Several fungi can cause a variety of infections: clinical manifestation and severity varies. True pathogens -- have the ability to cause infection in otherwise healthy individuals 2 24/08/2017 Opportunistic/deep mycoses which affect the respiratory system are: Cryptococcosis Aspergillosis Zygomycosis True pathogens are: Blastomycosis Seldom severe Treatment not required unless extensive tissue Coccidioidomycosis destruction compromising respiratory status Histoplasmosis Or extrapulmonary fungal dissemination Paracoccidioidomycosis COMMON PATHOGENS OBTAINED FROM SPECIMENS OF PATIENTS WITH RESPIRATORY DISEASE Fungi Common site of Mode of Infectious Clinical -
Turning on Virulence: Mechanisms That Underpin the Morphologic Transition and Pathogenicity of Blastomyces
Virulence ISSN: 2150-5594 (Print) 2150-5608 (Online) Journal homepage: http://www.tandfonline.com/loi/kvir20 Turning on Virulence: Mechanisms that underpin the Morphologic Transition and Pathogenicity of Blastomyces Joseph A. McBride, Gregory M. Gauthier & Bruce S. Klein To cite this article: Joseph A. McBride, Gregory M. Gauthier & Bruce S. Klein (2018): Turning on Virulence: Mechanisms that underpin the Morphologic Transition and Pathogenicity of Blastomyces, Virulence, DOI: 10.1080/21505594.2018.1449506 To link to this article: https://doi.org/10.1080/21505594.2018.1449506 © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group© Joseph A. McBride, Gregory M. Gauthier and Bruce S. Klein Accepted author version posted online: 13 Mar 2018. Submit your article to this journal Article views: 15 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=kvir20 Publisher: Taylor & Francis Journal: Virulence DOI: https://doi.org/10.1080/21505594.2018.1449506 Turning on Virulence: Mechanisms that underpin the Morphologic Transition and Pathogenicity of Blastomyces Joseph A. McBride, MDa,b,d, Gregory M. Gauthier, MDa,d, and Bruce S. Klein, MDa,b,c a Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, USA; b Division of Infectious Disease, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, 1675 Highland Avenue, Madison, WI 53792, USA; c Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, 1550 Linden Drive, Madison, WI 53706, USA. -
1 Recurrent Loss of Abaa, a Master Regulator of Asexual Development in Filamentous Fungi
bioRxiv preprint doi: https://doi.org/10.1101/829465; this version posted November 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Recurrent loss of abaA, a master regulator of asexual development in filamentous fungi, 2 correlates with changes in genomic and morphological traits 3 4 Matthew E. Meada,*, Alexander T. Borowskya,b,*, Bastian Joehnkc, Jacob L. Steenwyka, Xing- 5 Xing Shena, Anita Silc, and Antonis Rokasa,# 6 7 aDepartment of Biological Sciences, Vanderbilt University, Nashville, Tennessee, USA 8 bCurrent Address: Department of Botany and Plant Sciences, University of California Riverside, 9 Riverside, California, USA 10 cDepartment of Microbiology and Immunology, University of California San Francisco, San 11 Francisco, California, USA 12 13 Short Title: Recurrent loss of abaA across Eurotiomycetes 14 #Address correspondence to Antonis Rokas, [email protected] 15 16 *These authors contributed equally to this work 17 18 19 Keywords: Fungal asexual development, abaA, evolution, developmental evolution, 20 morphology, binding site, Histoplasma capsulatum, regulatory rewiring, gene regulatory 21 network, evo-devo 22 1 bioRxiv preprint doi: https://doi.org/10.1101/829465; this version posted November 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 23 Abstract 24 Gene regulatory networks (GRNs) drive developmental and cellular differentiation, and variation 25 in their architectures gives rise to morphological diversity. -
Therapeutic Class Overview Onychomycosis Agents
Therapeutic Class Overview Onychomycosis Agents Therapeutic Class • Overview/Summary: This review will focus on the antifungal agents Food and Drug Administration (FDA)-approved for the treatment of onychomycosis.1-9 Onychomycosis is a progressive infection of the nail bed which may extend into the matrix or plate, leading to destruction, deformity, thickening and discoloration. Of note, these agents are only indicated when specific types of fungus have caused the infection, and are listed in Table 1. Additionally, ciclopirox is only FDA-approved for mild to moderate onychomycosis without lunula involvement.1 The mechanisms by which these agents exhibit their antifungal effects are varied. For ciclopirox (Penlac®) the exact mechanism is unknown. It is believed to block fungal transmembrane transport, causing intracellular depletion of essential substrates and/or ions and to interfere with ribonucleic acid (RNA) and deoxyribonucleic acid (DNA).1 The azole antifungals, efinaconazole (Jublia®) and itraconazole tablets (Onmel®) and capsules (Sporanox®) works via inhibition of fungal lanosterol 14-alpha-demethylase, an enzyme necessary for the biosynthesis of ergosterol. By decreasing ergosterol concentrations, the fungal cell membrane permeability is increased, which results in leakage of cellular contents.2,5,6 Griseofulvin microsize (Grifulvin V®) and ultramicrosize (GRIS-PEG®) disrupts the mitotic spindle, arresting metaphase of cell division. Griseofulvin may also produce defective DNA that is unable to replicate. The ultramicrosize tablets are absorbed from the gastrointestinal tract at approximately one and one-half times that of microsize griseofulvin, which allows for a lower dose of griseofulvin to be administered.3,4 Tavaborole (Kerydin®), is an oxaborole antifungal that interferes with protein biosynthesis by inhibiting leucyl-transfer ribonucleic acid (tRNA) synthase (LeuRS), which prevents translation of tRNA by LeuRS.7 The final agent used for the treatment of onychomycosis, terbinafine hydrochloride (Lamisil®), is an allylamine antifungal. -
Pulmonary Aspergillosis: What CT Can Offer Before Radiology Section It Is Too Late!
DOI: 10.7860/JCDR/2016/17141.7684 Review Article Pulmonary Aspergillosis: What CT can Offer Before Radiology Section it is too Late! AKHILA PRASAD1, KSHITIJ AGARWAL2, DESH DEEPAK3, SWAPNDEEP SINGH ATWAL4 ABSTRACT Aspergillus is a large genus of saprophytic fungi which are present everywhere in the environment. However, in persons with underlying weakened immune response this innocent bystander can cause fatal illness if timely diagnosis and management is not done. Chest infection is the most common infection caused by Aspergillus in human beings. Radiological investigations particularly Computed Tomography (CT) provides the easiest, rapid and decision making information where tissue diagnosis and culture may be difficult and time-consuming. This article explores the crucial role of CT and offers a bird’s eye view of all the radiological patterns encountered in pulmonary aspergillosis viewed in the context of the immune derangement associated with it. Keywords: Air-crescent, Fungal ball, Halo sign, Invasive aspergillosis INTRODUCTION diagnostic pitfalls one encounters and also addresses the crucial The genus Aspergillus comprises of hundreds of fungal species issue as to when to order for the CT. ubiquitously present in nature; predominantly in the soil and The spectrum of disease that results from the Aspergilla becoming decaying vegetation. Nearly, 60 species of Aspergillus are a resident in the lung is known as ‘Pulmonary Aspergillosis’. An medically significant, owing to their ability to cause infections inert colonization of pulmonary cavities like in cases of tuberculosis in human beings affecting multiple organ systems, chiefly the and Sarcoidosis, where cavity formation is quite common, makes lungs, paranasal sinuses, central nervous system, ears and skin. -
HIV Infection and AIDS
G Maartens 12 HIV infection and AIDS Clinical examination in HIV disease 306 Prevention of opportunistic infections 323 Epidemiology 308 Preventing exposure 323 Global and regional epidemics 308 Chemoprophylaxis 323 Modes of transmission 308 Immunisation 324 Virology and immunology 309 Antiretroviral therapy 324 ART complications 325 Diagnosis and investigations 310 ART in special situations 326 Diagnosing HIV infection 310 Prevention of HIV 327 Viral load and CD4 counts 311 Clinical manifestations of HIV 311 Presenting problems in HIV infection 312 Lymphadenopathy 313 Weight loss 313 Fever 313 Mucocutaneous disease 314 Gastrointestinal disease 316 Hepatobiliary disease 317 Respiratory disease 318 Nervous system and eye disease 319 Rheumatological disease 321 Haematological abnormalities 322 Renal disease 322 Cardiac disease 322 HIV-related cancers 322 306 • HIV INFECTION AND AIDS Clinical examination in HIV disease 2 Oropharynx 34Neck Eyes Mucous membranes Lymph node enlargement Retina Tuberculosis Toxoplasmosis Lymphoma HIV retinopathy Kaposi’s sarcoma Progressive outer retinal Persistent generalised necrosis lymphadenopathy Parotidomegaly Oropharyngeal candidiasis Cytomegalovirus retinitis Cervical lymphadenopathy 3 Oral hairy leucoplakia 5 Central nervous system Herpes simplex Higher mental function Aphthous ulcers 4 HIV dementia Kaposi’s sarcoma Progressive multifocal leucoencephalopathy Teeth Focal signs 5 Toxoplasmosis Primary CNS lymphoma Neck stiffness Cryptococcal meningitis 2 Tuberculous meningitis Pneumococcal meningitis 6 -
PRIOR AUTHORIZATION CRITERIA BRAND NAME (Generic) SPORANOX ORAL CAPSULES (Itraconazole)
PRIOR AUTHORIZATION CRITERIA BRAND NAME (generic) SPORANOX ORAL CAPSULES (itraconazole) Status: CVS Caremark Criteria Type: Initial Prior Authorization Policy FDA-APPROVED INDICATIONS Sporanox (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Sporanox Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. Compendial Uses Coccidioidomycosis2,3 -
List Item Posaconazole SP-H-C-611-II
European Medicines Agency London, 4 December 2006 Product Name: POSACONAZOLE SP Procedure number: EMEA/H/C/611/II/01 authorised SCIENTIFIC DISCUSSION longer no product Medicinal 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: [email protected] http://www.emea.europa.eu 1 Introduction Fungal infections are a major cause of morbidity and mortality in immunocompromised patients. Filamentous mould and yeast-like fungi are ubiquitous organisms found worldwide in many different media. The Candida species are the most common cause of fungal infections. However, epidemiologic shifts have begun to occur, most likely due to the prophylactic and empiric use of antifungal agents. Emerging fungal pathogens, such as Aspergillus, Fusarium, and Zygomycetes, are changing the clinical spectrum of fungal diagnoses. Pathogens General risk factors for invasive fungal infections are exposure to pathogens, an impaired immune system, and fungal spores. The presence of a colonised environment, partnered with a disruption in a physiologic barrier, potentiates the risk of an invasive fungal infection in an immunologically impaired host, such as a patient infected with HIV, someone taking chronic systemic steroids, or a transplant recipient. In addition, contaminated implanted devices (e.g., catheters, prostheses), external devices (e.g., contact lenses), and community reservoirs (e.g., hand lotion, pepper shakers) have all been implicated as sources of fungal outbreaks. Candida albicans continues to be the most frequent cause of invasive fungal infections in most patient populations. However, prophylaxis and the widespread use of antifungal agents as empiric therapy for neutropenic fever have led to a shift in the epidemiology of invasive Candida infections. -
25 Chrysosporium
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Universidade do Minho: RepositoriUM 25 Chrysosporium Dongyou Liu and R.R.M. Paterson contents 25.1 Introduction ..................................................................................................................................................................... 197 25.1.1 Classification and Morphology ............................................................................................................................ 197 25.1.2 Clinical Features .................................................................................................................................................. 198 25.1.3 Diagnosis ............................................................................................................................................................. 199 25.2 Methods ........................................................................................................................................................................... 199 25.2.1 Sample Preparation .............................................................................................................................................. 199 25.2.2 Detection Procedures ........................................................................................................................................... 199 25.3 Conclusion .......................................................................................................................................................................200 -
Fungal Diseases
Abigail Zuger Fungal Diseases For creatures your size I offer a free choice of habitat, so settle yourselves in the zone that suits you best, in the pools of my pores or the tropical forests of arm-pit and crotch, in the deserts of my fore-arms, or the cool woods of my scalp Build colonies: I will supply adequate warmth and moisture, the sebum and lipids you need, on condition you never do me annoy with your presence, but behave as good guests should not rioting into acne or athlete's-foot or a boil. from "A New Year Greeting" by W.H. Auden. Introduction Most of the important contacts between human beings and the fungi occur outside medicine. Fungi give us beer, bread, antibiotics, mushroom omelets, mildew, and some devastating crop diseases; their ability to cause human disease is relatively small. Of approximately 100,000 known species of fungi, only a few hundred are human pathogens. Of these, only a handful are significant enough to be included in medical texts and introductory courses like this one. On the other hand, while fungal virulence for human beings is uncommon, the fungi are not casual pathogens. In the spectrum of infectious diseases, they can cause some of the most devastating and stubborn infections we see. Most human beings have a strong natural immunity to the fungi, but when this immunity is breached the consequences can be dramatic and severe. As modern medicine becomes increasingly adept in prolonging the survival of some patients with naturally-occurring immunocompromise (diabetes, cancer, AIDS), and causing iatrogenic immunocompromise in others (antibiotics, cytotoxic and MID 25 & 26 immunomodulating drugs), fungal infections are becoming increasingly important. -
Valley Fever a K a Coccidioidomycosis Coccidioidosis Coccidiodal Granuloma San Joaquin Valley Fever Desert Rheumatism Valley Bumps Cocci Cox C
2019 Lung Infection Symposium - Libke 10/26/2019 58 YO ♂ • 1974 PRESENTED WITH HEADACHE – DX = COCCI MENINGITIS WITH HYDROCEPHALUS – Rx = IV AMPHOTERICIN X 6 WKS – VP SHUNT – INTRACISTERNAL AMPHO B X 2.5 YRS (>200 PUNCTURES) • 1978 – 2011 VP SHUNT REVISIONS X 5 • 1974 – 2019 GAINFULLY EMPLOYED, RAISED FAMILY, RETIRED AND CALLS OCCASIONALLY TO SEE HOW I’M DOING. VALLEY FEVER A K A COCCIDIOIDOMYCOSIS COCCIDIOIDOSIS COCCIDIODAL GRANULOMA SAN JOAQUIN VALLEY FEVER DESERT RHEUMATISM VALLEY BUMPS COCCI COX C 1 2019 Lung Infection Symposium - Libke 10/26/2019 COCCIDIOIDOMYCOSIS • DISEASE FIRST DESCRIBED IN 1892 – POSADAS –ARGENTINA – RIXFORD & GILCHRIST - CALIFORNIA – INITIALLY THOUGHT PARASITE – RESEMBLED COCCIDIA “COCCIDIOIDES” – “IMMITIS” = NOT MINOR COCCIDIOIDOMYCOSIS • 1900 ORGANISM IDENTIFIED AS FUNGUS – OPHULS AND MOFFITT – ORGANISM CULTURED FROM TISSUES OF PATIENT – LIFE CYCLE DEFINED – FULFULLED KOCH’S POSTULATES 2 2019 Lung Infection Symposium - Libke 10/26/2019 COCCIDIOIDOMYCOSIS • 1932 ORGANISM IN SOIL SAMPLE FROM DELANO – UNDER BUNKHOUSE OF 4 PATIENTS – DISEASE FATAL • 1937 DICKSON & GIFFORD CONNECTED “VALLEY FEVER” TO C. IMMITIS – USUALLY SELF LIMITED – FREQUENTLY SEEN IN SAN JOAQUIN VALLEY – RESPIRATORY TRACT THE PORTAL OF ENTRY The usual cause for coccidioidomycosis in Arizona is C. immitis A. True B. False 3 2019 Lung Infection Symposium - Libke 10/26/2019 COCCIDIOIDAL SPECIES • COCCIDIOIDES IMMITIS – CALIFORNIA • COCCIDIOIDES POSADASII – NON-CALIFORNIA • ARIZONA, MEXICO • OVERLAP IN SAN DIEGO AREA THE MICROBIAL WORLD • PRIONS